Rationale for anti-AIDS chemotherapy directed at HIV-1 infected dendritic cells in seropositive individuals prior to the appearance of ARC and AIDS.
An approach to anti-AIDS chemotherapy is presented from the point of view of treating seropositive individuals by eliminating the infected dendritic cells that are the in vivo target of HIV-1. Special attention is given to the treatment of Langerhans (dendritic) cells in the skin and epithelia that are infected in vivo by HIV and are involved in the development of the symptoms leading to AIDS and ARC. Since HIV is released through the cervical and vaginal epithelia in seropositive women, it is suggested that combined local treatment of vaginal epithelium with steroids that inactivate dendritic cells and azidothymidine (AZT) that inhibits HIV-1 replication might prevent virus dissemination. Abrogation of HIV-1 transmission will help to prevent its spread throughout the heterosexual population. Thus a new rationale for anti-AIDS treatment is presented, namely selective elimination of HIV-1 infected dendritic cells in the skin and epithelia of infected individuals before the appearance of ARC or AIDS. Subsequent restoration of dendritic cells in HIV-1-infected persons (and in AIDS patients) by means of orally administered retinoids in combination with an antiviral drug might be a useful approach to prevent or delay AIDS.
Becker
Y
Y
Department of Molecular Virology, Faculty of Medicine, Hebrew University, Jerusalem, Israel.
D000386:AIDS-Related Complex / Q000517:prevention & control*; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000187:drug effects / Q000382:microbiology* / Q000528:radiation effects; D004359:Drug Therapy, Combination; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification / Q000528:radiation effects; D006801:Humans; D015201:Meta-Analysis as Topic; D014212:Tretinoin / Q000627:therapeutic use; D014467:Ultraviolet Therapy; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D015215:Zidovudine; D014212:Tretinoin